IMCR

Immunocore (IMCR)

Immunocore Holdings PLC

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:IMCR

1 2 3 4 5 6 7 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/01	21 : 00	GlobeNewswire Inc.	Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response	NASDAQ:IMCR	Immunocore Holdings PLC
2024/06/01	05 : 21	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMCR	Immunocore Holdings PLC
2024/06/01	05 : 05	GlobeNewswire Inc.	Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/31	05 : 00	GlobeNewswire Inc.	Immunocore to present at the Jefferies Global Healthcare Conference	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/29	20 : 00	GlobeNewswire Inc.	Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/29	05 : 17	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/29	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/29	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/29	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/29	05 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/24	05 : 50	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/08	20 : 13	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/08	20 : 00	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:IMCR	Immunocore Holdings PLC
2024/05/08	20 : 00	GlobeNewswire Inc.	Immunocore reports first quarter financial results and provides a business update	NASDAQ:IMCR	Immunocore Holdings PLC
2024/04/24	23 : 00	GlobeNewswire Inc.	Immunocore announces upcoming presentation and posters at ASCO 2024	NASDAQ:IMCR	Immunocore Holdings PLC
2024/04/05	05 : 00	GlobeNewswire Inc.	Immunocore to present at upcoming investor conferences	NASDAQ:IMCR	Immunocore Holdings PLC
2024/03/06	06 : 30	GlobeNewswire Inc.	Immunocore presented two posters at CROI 2024	NASDAQ:IMCR	Immunocore Holdings PLC
2024/03/01	21 : 00	GlobeNewswire Inc.	Immunocore to present at upcoming investor conferences	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/29	06 : 19	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/29	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/28	21 : 34	GlobeNewswire Inc.	Immunocore reports fourth quarter and full year 2023 financial results and provides a business update	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/28	21 : 33	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/27	08 : 46	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/22	21 : 00	GlobeNewswire Inc.	Immunocore announces clinical trial collaboration and supply agreement with Bristol Myers Squibb to evaluate IMC-F106C (PRAME HLA-A02) in combination with nivolumab in its registrational Phase 3 first-line advanced cutaneous melanoma trial	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/22	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/22	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/22	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/22	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/22	06 : 15	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:IMCR	Immunocore Holdings PLC
2024/02/21	21 : 00	GlobeNewswire Inc.	Immunocore to report fourth quarter and full year 2023 financial results and host call on February 28, 2024	NASDAQ:IMCR	Immunocore Holdings PLC